Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolterodine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 9/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolterodine SCHEMBL29635996 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL3064 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL580446 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL820421 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL36882 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL1260827 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL4840247 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL9221238 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL617185 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL1262758 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3442516-B1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIV CANBERRA (AU) | 2025-11-12 | — | — | EP | claimed |
| EP-4079311-B1 | NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2025-10-01 | — | — | EP | claimed |
| EP-2968880-B1 | DRUG DELIVERY DEVICES WITH DRUG-PERMEABLE COMPONENT | TARIS BIOMEDICAL LLC (US) | 2025-04-30 | — | — | EP | claimed |
| EP-3441087-B1 | METHODS OF TREATING CHRONIC PAIN | TEVA PHARMACEUTICALS INT GMBH (CH) | 2025-02-19 | — | — | EP | claimed |
| EP-3357945-B1 | ADHESIVE POLYMER AND MEDICAL ADHESIVE PATCH | TEIKOKU SEIYAKU KK (JP) | 2024-10-30 | — | — | EP | claimed |
| EP-4126138-B1 | AEROSOL DELIVERY OF AT LEAST TWO LIQUID COMPOSITIONS | INVOX BELGIUM NV (BE) | 2024-10-16 | — | — | EP | claimed |
| EP-3697386-B1 | LIQUID COMPOSITIONS FOR PERORAL USE COMPRISING PHOSPHATIDYLGLYCEROL DERIVATIVES AND THIXOTROPIC EXCIPIENTS FOR TREATING CARDIAC CHANNELOPATHIES CAUSED BY PHARMACOLOGICAL AGENTS | SIGNPATH PHARMA INC (US) | 2023-07-26 | — | — | EP | claimed |
| EP-3728280-B1 | METHOD FOR IMPROVING THE ORAL BIOAVAILABILITY OF A DRUG | PHARMACYTICS B V (NL) | 2023-06-28 | — | — | EP | claimed |
| EP-3151837-B1 | PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES | SIGNPATH PHARMA INC (US) | 2023-03-15 | — | — | EP | claimed |
| EP-3319613-B1 | USE OF AMINE CARBOXYBORANES AS THERAPEUTIC DELIVERY OF CARBON MONOXIDE AND AS GENERAL DRUG DELIVERY SYSTEM IN THE PRESENCE OF REACTIVE OXYGEN SPECIES | UNIV NEW YORK STATE RES FOUND (US) | 2023-02-22 | — | — | EP | claimed |
| EP-3534904-B1 | USE OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE IN THE TREATMENT OF CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS | METRIOPHARM AG (CH) | 2022-03-16 | — | — | EP | claimed |
| EP-4603095-A2 | IMPROVED PHARMACEUTICAL FORMULATIONS | Ferring B.V. (NL) | 2025-08-20 | — | — | EP | disclosed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| EP-3787596-B1 | IMPROVED PHARMACEUTICAL FORMULATIONS | FERRING BV (NL) | 2025-06-25 | — | — | EP | disclosed |
| WO-2022223174-A1 | SYRINGE STERILIZATION METHOD | FARCO-PHARMA GMBH (DE) | 2022-10-27 | — | — | WO | disclosed |
| US-11458454-B2 | Granular functionalized silica, process for preparation thereof and use thereof | EVONIK OPERATIONS GMBH (DE) | 2022-10-04 | — | — | US | disclosed |
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-08-30 | — | — | US | disclosed |
| CN-110840847-B | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 沃泰克斯药物股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | CHRM3 194/4885CHRM2 220/4885CHRM1 481/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CHRM3 194/4885CHRM2 220/4885CHRM1 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.